Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Innovation Building with BioEscalator, EnaraBio and Boehringer Ingelheim logos

Enara Bio, an SV Health backed start-up, was founded in 2016 using technology developed at the Francis Crick Institute, London. The company joined the BioEscalator, Oxford University’s biotech incubator, in 2018 as Ervaxx with five employees and has since developed two proprietary platforms EDAPT™ and Dark Antigen™, rebranded as Enara Bio and grown the team to twenty-seven. Enara Bio has utilised its strong relationship with Oxford academics, including immunopeptidomics expert Dr Nicola Ternette and Vaccitech’s Professor Adrian Hill, both of the Nuffield Department of Medicine, to develop its innovative technologies.  It will now utilise Boehringer’s wealth of big pharma development resources to help drive discoveries further towards the clinic.

The partnership will provide additional funding to advance Dark Antigen research along with further independent validation of Enara’s novel EDAPT™ platform.

We’re excited to be partnered with an innovation-led company that has built considerable expertise in cancer vaccines and immune-oncology - Kevin Pojasek, CEO Enara Bio

Read the full story on the BioEscalator website

Similar stories

Meta must do better - data from social media giant essential to mental health research

People are rightly sceptical about scientific discoveries made in secret or without scrutiny. And anyone claiming to have found a new planet with a toy telescope, would not be taken seriously. Recent leaks of internal Facebook research on the mental health of children and young people have caused a great stir on both sides of the Atlantic.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Oxford researchers honoured by British Society for Immunology

Four researchers from the University of Oxford have been recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology, with the awards being announced at the recent British Society for Immunology Congress held in Edinburgh.

Medical Sciences researchers scoop 2021 Times Higher Education Awards

Coronavirus researchers from across Medical Sciences have been honoured at the 2021 Times Higher Education (THE) Awards.

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.